현재 NCFB의 치료제로 승인된 디펩티딜 펩티다제 1(DPP1) 억제제는 BRINSUPRI(brensocatib)뿐입니다. 디펩티딜 펩티다제 1(DPP1) 억제제는 조직 장애 및 만성 염증의 주요 중재자인 호중구 세린 프로테아제의 업스트림 활성화를 표적으로 하는 유망한 치료제입니다. NCFB와 COPD와 같은 호흡기 질환에서 이러한 약물은 기도 파괴와 악화를 유발하는 프로테아제 활성을 감소시키는 데 도움이 됩니다. 새로운 용도로는 과도한 호중구 활성이 중요한 역할을 하는 피부 질환과 자가면역 질환을 들 수 있습니다. 이 부류의 신규 화합물은 염증 캐스케이드 초기에 개입하여 질병 개질 효과를 제공하고 기존의 항염증 요법에 비해 더 표적화된 접근법을 제공하는 것을 목표로 합니다. 호중구성 염증과 프로테아제를 통한 조직 부상을 완화함으로써 디펩티딜 펩티다제 1(DPP1) 억제제는 미충족 수요(Unmet Needs)가 높은 질병의 예후를 향상시킬 것으로 기대됩니다.
본 보고서는 디펩티딜 펩티다제 1(DPP1)/카텝신 C 억제제의 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대한 조사 분석을 통해 각 지역 시장 규모와 예측, 현재 치료법, 신약, 미충족 수요(Unmet Needs) 등의 정보를 제공합니다.
Request a sample to unlock the CAGR for "DPP1 inhibitor Market Forecast"
DelveInsight's "Dipeptidyl Peptidase 1 (DPP1)/Cathepsin C Inhibitor Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the DPP1 inhibitor, competitive landscape, eligible patient population as well as the DPP1 inhibitor therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The DPP1 inhibitor market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM DPP1 inhibitor market size from 2025 to 2034. The report also covers current DPP1 inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Study Period 2020 to 2034
Forecast Period 2024-2034
Geographies Covered * The US, EU4 (Germany, France, Italy, and Spain) and UK, Japan
DPP1 inhibitor Market * Total Market Size
DPP1 inhibitor Companies Insmed Incorporated, Boehringer Ingelheim, Shanghai Fosun Pharmaceutical, Expedition Therapeutics, Melodia Therapeutics, Alivexis, and others.
DPP1 inhibitor Epidemiology Segmentation * Total Prevalent Cases in Selected Indications for DPP1 Inhibitor
Key Factors Driving the Growth of DPP1 Inhibitors Market
Growing DPP1 Inhibitors Target Patient Pool
The increasing prevalence of chronic respiratory diseases, such as bronchiectasis, has expanded the patient population in need of effective treatments. In 2024, approximately 390K individuals in the US were diagnosed with NCFB, while millions more are estimated to be affected globally. This figure is projected to exceed 470K by 2034. Additionally, the rising prevalence of diseases such as ANCA-associated vasculitis, COPD, SLE, Hidradenitis suppurativa, Palmoplantar pustulosis, IBD, and others will propel the DPP1 inhibitor market.
Launch of Insmed's BRINSUPRI
Insmed's BRINSUPRI (brensocatib) has reached a key regulatory milestone, emerging as the first FDA-approved DPP inhibitor and the first therapy specifically approved for NCFB. As the only treatment designed exclusively for this condition, its approval represents a major scientific breakthrough, addressing a market with persistent unmet needs.
Rising DPP1 Inhibitors Clinical Trial Activity
Following the BRINSUPRI approval, leading companies such as Boehringer Ingelheim [Verducatib (BI 1291583) for bronchiectasis], Fosun Pharma/Expedition Therapeutics (XH-S004 for NCFB and COPD), Haisco Pharmaceutical Group/Chiesi (HSK31858 for NCFB and asthma), and Melodia Therapeutics/Alivexis (MDI-0151, currently in preclinical stages but showing potential in ANCA-associated vasculitis, bronchiectasis, COPD, and other conditions), geared up to launch their products in the DPP1 inhibitor market.
Strategic Collaborations and DPP1 Inhibitors Market Expansion
Partnerships between pharmaceutical companies and healthcare providers have accelerated the development and distribution of DPP1 inhibitors. For example, Chiesi Group's licensing agreement with Haisco Pharmaceutical to develop and commercialize HSK31858, a novel reversible DPP1 inhibitor, exemplifies strategic collaboration.
Dipeptidyl Peptidase 1 (DPP1)/Cathepsin C Inhibitor Treatment Market
Dipeptidyl Peptidase 1 (DPP1)/Cathepsin C Inhibitor Overview
DPP1 inhibitors are agents that block the activity of DPP1, an enzyme that activates neutrophil serine proteases during neutrophil development. By inhibiting DPP1, these compounds reduce excessive protease activity, which drives tissue damage and chronic inflammation. They are being investigated across multiple inflammatory and respiratory diseases where neutrophilic inflammation plays a central role.
These inhibitors work by preventing the activation of enzymes that cause airway damage, mucus overproduction, and recurrent infections. By targeting this upstream mechanism, oral DPP1 inhibitors aim to interrupt the cycle of inflammation and tissue destruction, potentially modifying disease progression rather than just alleviating symptoms. Their novel mechanism and oral administration make them an important emerging approach for conditions marked by unchecked neutrophil-driven damage.
Epidemiology of Top Indications
Indication Estimated Prevalent Cases in 2024 in the US
Chronic Obstructive Pulmonary Disease (COPD) ~16,500,000
Non-Cystic Fibrosis Bronchiectasis (NCFB) ~389,000
Systemic Lupus Erythematosus (SLE) ~530,000
Hidradenitis suppurativa ~895,000
NOTE: The list of indications is not exhaustive and will be provided in the final report. Also, numbers are indicative and are subject to change as per report updation.
Key Updates Dipeptidyl Peptidase 1 (DPP1)/Cathepsin C Inhibitor
The drug chapter segment of the DPP1 inhibitor report encloses a detailed analysis of approved as well as emerging drugs in late, mid, early, and preclinical-stage (Phase III, Phase II, Phase I, and preclinical) pipeline drugs. It also helps understand the DPP1 inhibitor clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
DPP1 Inhibitor Marketed Drugs
BRINSUPRI (brensocatib): Insmed Incorporated
BRINSUPRI is a small molecule, once-daily, oral, reversible inhibitor of DPP1 indicated for the treatment of NCFB in adult and pediatric patients 12 years of age or older. Recently approved, BRINSUPRI is designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in NCFB. BRINSUPRI is also being evaluated for its potential role in other neutrophil-mediated diseases.
In August 2025, the US Food and Drug Administration (FDA) approved first-in-class BRINSUPRI (brensocatib 10 mg and 25 mg tablets) NCFB in adults and children 12 years and older. The efficacy of BRINSUPRI was assessed in two randomized, double-blind, placebo-controlled, clinical trials, ASPEN (NCT04594369) and WILLOW (NCT03218917).
DPP1 Inhibitor Emerging Drugs
Verducatib (BI 1291583): Boehringer Ingelheim
Verducatib is a novel DPP1 inhibitor with the potential to improve symptoms and quality of life for patients with bronchiectasis. Currently, Boehringer Ingelheim is investigating the efficacy, safety, and tolerability of verducatib versus placebo in individuals with bronchiectasis, independent of underlying etiologies in AIRTIVITY (NCT06872892), a Phase III, multicenter, multinational, prospective, randomized, double-blind, placebo-controlled trial.
Earlier, Verducatib received FDA breakthrough therapy designation in 2024 for the treatment of bronchiectasis.
XH-S004: Shanghai Fosun Pharmaceutical and Expedition Therapeutics
XH-S004 is a small molecule orally administered DPP-1 inhibitor independently developed by Fosun Pharma. It reduces inflammatory responses and blocks the infection cycle and airway structural damage by inhibiting DPP-1 and the neutrophil serine proteases activated by it.
As of now, XH-S004 is in Phase II clinical trials in China for the treatment of NCFB and in Phase Ib clinical trials for the treatment of COPD.
Comparison of Key Emerging DPP1 Inhibitors
Product Company Molecule type RoA Phase NCT ID Indication
Verducatib
(BI 1291583) Boehringer Ingelheim Small molecule Oral III NCT06872892 (AIRTIVITY) Bronchiectasis
XH-S004 Shanghai Fosun Pharmaceutical and Expedition Therapeutics Small molecule Oral II NCT06981091 NCFB
Ib NCT07035652 COPD
MDI-0151 Melodia Therapeutics and Alivexis Small molecule - Preclinical - IBD, SLE, Hidradenitis suppurativa, and Palmoplantar pustulosis
Currently, BRINSUPRI (brensocatib) is the only DPP1 inhibitor approved treatment option for NCFB. DPP1 inhibitors represent a promising treatment class that targets the upstream activation of neutrophil serine proteases, which are key mediators of tissue damage and chronic inflammation. In respiratory diseases like NCFB and COPD, these agents help reduce protease activity that drives airway destruction and exacerbations. Emerging applications also include dermatological and autoimmune conditions where excessive neutrophil activity plays a critical role. Novel compounds in this class aim to provide disease-modifying benefits by intervening early in the inflammatory cascade, offering a more targeted approach compared to conventional anti-inflammatory therapies. By reducing neutrophilic inflammation and protease-mediated tissue injury, DPP1 inhibitors hold promise for improving outcomes in conditions with significant unmet needs.
DPP-1 inhibition may also be a promising treatment avenue in other diseases where neutrophilic inflammation is implicated. Future directions include establishing direct and downstream effects of DPP-1 inhibitors in humans and seeking biomarkers to guide clinical application.
Several key players, including Boehringer Ingelheim, Shanghai Fosun Pharmaceutical and Expedition Therapeutics, Melodia Therapeutics and Alivexis, and others, are involved in developing drugs for the DPP1 inhibitor for various indications such as Bronchiectasis, COPD, NCFB, SLE, Hidradenitis suppurativa, Palmoplantar pustulosis, IBD, and others.
BRINSUPRI market forecast is dependent on factors such as therapy uptake in upcoming years, competitive stiffness in NCFB patient segment, key pricing decisions taken by Insmed, confidential discounts offered by the company, decision making by payers and HTA bodies in terms of accessibility and reimbursement in various countries, safety and efficacy parameters along with anticipated launches in wider geographies during 2025-2034.
Dipeptidyl Peptidase 1 (DPP1)/Cathepsin C Inhibitor Pipeline Development Activities
The DPP1 Inhibitor pipeline report provides insights into different DPP1 Inhibitor clinical trials within Phase III, Phase II, Phase I, and preclinical. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs at different stages is expected to generate immense opportunities for the DPP1 inhibitor market growth over the forecasted period.
DPP1 Inhibitor Pipeline development activities
The DPP1 Inhibitor clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for DPP1 inhibitor emerging therapies.
The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion. For example, in August 2025, Fosun Pharma's subsidiary, Fosun Pharma Industrial, signed a License Agreement with Expedition Therapeutics to grant Expedition the rights to develop, manufacture, and commercialize XH-S004 in all regions globally except the Chinese Mainland, Hong Kong SAR, and Macau SAR.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on DPP1 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the US. Centers such as the University of Tours, University of Dundee, Ninewells Hospital and Medical School, University of Birmingham, etc., were contacted.
Their opinion helps understand and validate current and emerging therapy treatment patterns or DPP1 inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
KOL Views
"DPP-1 inhibition with brensocatib had the greatest effect in reducing Cathepsin G activity in sputum and the least effect on PR3 activity. There may be multiple factors accounting for the differential response in neutrophil serine protease activity to DPP-1 inhibition. In the absence of a DPP-1 inhibitor, nearly all of the neutrophil serine protease zymogens are converted to active forms during neutrophil maturation."
MD, Ninewells Hospital and Medical School, UK
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated.
Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement Key Developments in 2025
Region/Country Key 2025 Developments
United States * Ongoing tariff threats and delays
Europe (EU-wide) * Joint Clinical Assessment launched (6 drugs under review)
Germany * AMNOG reform: focus on rebates & personalized medicine
France * Expanding use of health economic evaluations and value metrics
Italy * AIFA revised innovation criteria
Spain * Ongoing gradual reform of HTA and pricing system
United Kingdom * VPAG renegotiation delayed; sector plan postponed
China * Lower market access barriers, fair competition promoted
Japan * Structural pharmaceutical reform and focus on drug discovery
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Key Questions Answered In The DPP1 Inhibitor Market Report:
Reasons to buy DPP1 Inhibitor Market Forecast Report